Investors sold shares of Eli Lilly and Co (NYSE:LLY) on strength during trading on Monday. $50.20 million flowed into the stock on the tick-up and $132.59 million flowed out of the stock on the tick-down, for a money net flow of $82.39 million out of the stock. Of all companies tracked, Eli Lilly and had the 21st highest net out-flow for the day. Eli Lilly and traded up $0.49 for the day and closed at $77.34
LLY has been the topic of several analyst reports. Jefferies Group set a $93.00 price target on Eli Lilly and and gave the stock a “buy” rating in a report on Monday, February 26th. Goldman Sachs lowered Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $86.98 to $95.00 in a report on Tuesday, January 16th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a report on Tuesday, April 3rd. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price target for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Bank of America reduced their price target on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $92.84.
The firm has a market cap of $84,196.70, a PE ratio of 18.07, a PEG ratio of 1.43 and a beta of 0.26. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. Eli Lilly and’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.95 EPS. analysts forecast that Eli Lilly and Co will post 4.87 EPS for the current year.
In related news, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the sale, the insider now directly owns 4,130 shares in the company, valued at approximately $334,901.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,261 shares of company stock worth $1,225,085. 0.11% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of the business. Waldron LP increased its stake in Eli Lilly and by 15.5% during the fourth quarter. Waldron LP now owns 4,463 shares of the company’s stock worth $376,000 after purchasing an additional 600 shares during the period. East Coast Asset Management LLC. increased its stake in Eli Lilly and by 22.2% during the third quarter. East Coast Asset Management LLC. now owns 3,360 shares of the company’s stock worth $287,000 after purchasing an additional 610 shares during the period. Clear Investment Research LLC increased its stake in Eli Lilly and by 23.2% during the fourth quarter. Clear Investment Research LLC now owns 3,247 shares of the company’s stock worth $274,000 after purchasing an additional 611 shares during the period. Tompkins Financial Corp increased its stake in Eli Lilly and by 1.8% during the fourth quarter. Tompkins Financial Corp now owns 35,604 shares of the company’s stock worth $3,007,000 after purchasing an additional 613 shares during the period. Finally, Harbour Capital Advisors LLC increased its stake in Eli Lilly and by 2.8% during the fourth quarter. Harbour Capital Advisors LLC now owns 22,673 shares of the company’s stock worth $1,915,000 after purchasing an additional 622 shares during the period. Institutional investors own 77.66% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Traders Sell Shares of Eli Lilly and (LLY) on Strength (LLY)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/traders-sell-shares-of-eli-lilly-and-lly-on-strength-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.